ServiziMenu principale

<< Torna a "Studi Fase I"

J4G-OX-JZVA - An Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Advanced Solid Tumor Malignancies With FGFR3 Alterations.

Studio Clinico

Patologia: Carcinoma della vescica, Altre neoplasie

Osservazionale-Sperimentale: Sperimentale

Monocentrico-Multicentrico: Multicentrico

Randomizzato: No

Fase di studio: 1,

Richiesta mandatoria di tessuto: 

Linee di trattamento: Prima/N linee

Criteri di inclusione: 

- Have solid tumor cancer with an FGFR3 pathway alteration on molecular testing in tumor or blood sample that is deemed as actionable.
- Cohort A1 (Dose Escalation): Presence of an alteration in FGFR3 or its ligands.
- Cohort A2 (Dose Optimization): Histological diagnosis of urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 alteration.
- Cohorts B1, B2 and B3 (Dose Expansion): Histological diagnosis of urothelial cancer that is locally advanced or metastatic with a prespecified activating FGFR3 alteration.
- Cohort C (Dose Expansion): Must have histological diagnosis of a non-urothelial solid tumor malignancy that is locally advanced or metastatic with a prespecified activating FGFR3 alteration.

Measurability of disease:
- Cohort A1: Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1)
- Cohorts A2, B1, B2, B3, and C1: Measurable disease required as defined by RECIST v1.1

- Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country-specific regulations.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Prior Systemic Therapy Criteria:
- Cohort A1/C1: Participant has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating Investigator; OR the participant is refusing the remaining most appropriate standard of care treatment; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies.
- Cohort A2/B1/B2/B3: Participants must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.

FGFR inhibitor specific requirements:
- Cohort A1/A2: Prior FGFR inhibitor treatment is permitted, but not required.
- Cohort B1: Participants must have been previously treated with a FGFR inhibitor.
- Cohort B2, B3, C1: Participants must be FGFR inhibitor naïve.

Criteri di esclusione: 

- Participants with primary central nervous system (CNS) malignancy.
- Known or suspected history of uncontrolled CNS metastases.
- Current evidence of corneal keratopathy or retinal disorder.
- Have a history and/or current evidence of extensive tissue calcification.
- Any serious unresolved toxicities from prior therapy.
- Significant cardiovascular disease.
- Prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF).
- Active uncontrolled systemic infection or other clinically significant medical conditions.
- Participants who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment. Participants who have stopped breastfeeding may be enrolled.

Trattamento sperimentale: 

Loxo-435

Trattamento di controllo: 

Pembrolizumab (cohort B)

Centri partecipanti

Nord Italia

Ospedale San Raffaele di Milano
Via Olgettina 60 - 20132 Milano - MI

Riferimento: Prof. Andrea Necchi
Email: necchi.andrea@unisr.it

Informazioni Generali

Protocollo

Numero di iscrizione a registro: 2022-502755-59-00

Data di inserimento: 29.05.2024

Promotore

Eli Lilly and Company

Principal Investigator ITALIA

IRCCS Ospedale San Raffaele, Milano

Riferimento: Prof. Andrea Necchi

Telefono: 0226435789

Email: necchi.andrea@unisr.it

Localita: Milano

 

<< Torna a "Studi Fase I"

Apri